Should I buy or sell Erasca stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ERAS shares. View ERAS analyst ratings or view top-rated stocks .

What is Erasca's stock price target for 2024?

5 analysts have issued 12 month price targets for Erasca's stock. Their ERAS share price targets range from $6.00 to $11.00. On average, they expect the company's share price to reach $7.83 in the next year. This suggests a possible upside of 350.2% from the stock's current price. View analysts price targets for ERAS or view top-rated stocks among Wall Street analysts .

How have ERAS shares performed in 2024?

Erasca's stock was trading at $2.13 on January 1st, 2024. Since then, ERAS stock has decreased by 18.3% and is now trading at $1.74. View the best growth stocks for 2024 here .

When is Erasca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ERAS earnings forecast .

How were Erasca's earnings last quarter?

Erasca, Inc. (NASDAQ:ERAS) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.05.

What ETF holds Erasca's stock?

Loncar China Biopharma ETF holds 137,992 shares of ERAS stock, representing 1.26% of its portfolio.

Erasca (ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.

Who are Erasca's major shareholders?

Erasca's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (0.01%). Insiders that own company stock include Alexander W Casdin, Bihua Chen, Jonathan E Lim and Valerie Denise Harding Start. View institutional ownership trends .

How do I buy shares of Erasca?

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ERAS

Erasca (ERAS) Stock Price, News & Analysis

→ Will this $2 AI stock double overnight? (From Behind the Markets) (Ad)

Free ERAS Stock Alerts

$1.79

0.00 (0.00%)

(As of 04:37 PM ET)

Compare

Today's Range: $1.74
▼
$1.82
50-Day Range: $1.67
▼
$2.55
52-Week Range: $1.51
▼
$3.38

Volume: 570,186 shs
Average Volume: 794,834 shs
Market Capitalization: $271.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.83

Get Erasca alerts:

Erasca MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 350.2% Upside
$7.83 Price Target
Short Interest: Bearish
9.88% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.96) to ($1.03) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.57 out of 5 stars

Medical Sector

660th out of 918 stocks

Pharmaceutical Preparations Industry

293rd out of 417 stocks

3.4

Analyst's Opinion

Consensus Rating
Erasca has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Erasca has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.88% of the float of Erasca has been sold short.
Short Interest Ratio / Days to Cover
Erasca has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
Change versus previous month
Short interest in Erasca has recently decreased by 1.66%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Erasca does not currently pay a dividend.
Dividend Growth
Erasca does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ERAS.

1.1

News and Social Media Coverage

News Sentiment
Erasca has a news sentiment score of -0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Erasca this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for ERAS on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
6 people have added Erasca to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Erasca insiders have not sold or bought any company stock.
Percentage Held by Insiders
29.80% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Erasca are expected to decrease in the coming year, from ($0.96) to ($1.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Erasca is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Erasca is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Erasca has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

Click here to learn more >>>

About Erasca Stock (NASDAQ:ERAS)

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

ERAS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ERAS Stock News Headlines

April 16, 2024 | finance.yahoo.com

Institutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year losses

April 9, 2024 | fool.com

Erasca (NASDAQ: ERAS)

April 19, 2024 | Behind the Markets (Ad)

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

April 3, 2024 | markets.businessinsider.com

Erasca’s Promising Naporafenib Data and Financial Stability Merit a Buy Rating

April 1, 2024 | finance.yahoo.com

Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript

March 31, 2024 | seekingalpha.com

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

March 29, 2024 | finanznachrichten.de

Erasca, Inc.: Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

March 29, 2024 | finance.yahoo.com

Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...

April 19, 2024 | Behind the Markets (Ad)

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

March 29, 2024 | markets.businessinsider.com

Erasca’s Strong Clinical Data and Enhanced Financial Position Support Buy Rating

March 28, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Erasca (ERAS)

March 28, 2024 | msn.com

Erasca to get $45M funding via private placement

March 28, 2024 | marketwatch.com

Erasca Shares Climb After 4Q Loss Narrows, $45 Million Private Placement

March 27, 2024 | investorplace.com

ERAS Stock Earnings: Erasca Beats EPS for Q4 2023

March 27, 2024 | globenewswire.com

Erasca Announces $45 Million Oversubscribed Private Placement Financing

March 27, 2024 | globenewswire.com

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

March 21, 2024 | msn.com

Ocugen hits a 52-week high after decision to lower quorum requirement

February 27, 2024 | finance.yahoo.com

ERAS Mar 2024 2.000 put

February 17, 2024 | finance.yahoo.com

ERAS Mar 2024 2.500 call

February 15, 2024 | msn.com

Erasca collaborates with Novartis on cancer therapy trials

February 14, 2024 | finance.yahoo.com

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

February 1, 2024 | finance.yahoo.com

Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 9, 2024 | finance.yahoo.com

Is Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?

January 7, 2024 | benzinga.com

Erasca Stock (NASDAQ:ERAS), Analyst Ratings, Price Targets, Predictions

January 6, 2024 | msn.com

B of A Securities Downgrades Erasca (ERAS)

January 3, 2024 | finance.yahoo.com

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 13, 2023 | markets.businessinsider.com

Strong Buy Rating for Erasca’s Stock on FDA Fast Track Designation and Market Expansion Potential

See More Headlines

Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ERAS
CUSIP: N/A
CIK: 1761918
Web: www.erasca.com
Phone: 858-465-6511
Fax: N/A
Employees: 129
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.83
High Stock Price Target: $11.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +337.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-125,040,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -35.60%
Return on Assets: -29.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.26
Quick Ratio: 12.26

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.10 per share
Price / Book: 0.85

Miscellaneous

Outstanding Shares: 151,490,000
Free Float: 106,349,000
Market Cap: $271.17 million
Optionable: Optionable
Beta: 1.10

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Jonathan E. Lim M.D. (Age 52)
Co-Founder, Chairman & CEO
Comp: $940.32k
Dr. David M. Chacko M.D. (Age 40)
CFO & Chief Business Officer
Comp: $616.76k
Dr. Michael D. Varney Ph.D. (Age 66)
Chairman of Research & Development, Scientific Advisory Board Member and Director
Comp: $83.26k
Dr. Nik Chetwyn Ph.D.
Chief Operating Officer
Mr. Ebun S. Garner J.D. (Age 52)
Esq., General Counsel & Corporate Secretary
Comp: $510.98k
Dr. Lisa Tesvich-Bonora Ph.D.
Chief People Officer
Mr. Brian L. Baker CPA (Age 57)
M.S., Senior Vice President of Finance
Ms. Chandra D. Lovejoy M.S. (Age 53)
Chief Regulatory Affairs Officer
Dr. Robert Shoemaker Ph.D. (Age 43)
Senior Vice President of Research
Dr. Shannon R. Morris M.D. (Age 54)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ERAS Stock Analysis - Frequently Asked Questions

Should I buy or sell Erasca stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ERAS shares.
View ERAS analyst ratings or view top-rated stocks.
What is Erasca's stock price target for 2024?: 5 analysts have issued 12 month price targets for Erasca's stock. Their ERAS share price targets range from $6.00 to $11.00. On average, they expect the company's share price to reach $7.83 in the next year. This suggests a possible upside of 350.2% from the stock's current price.
View analysts price targets for ERAS or view top-rated stocks among Wall Street analysts.
How have ERAS shares performed in 2024?: Erasca's stock was trading at $2.13 on January 1st, 2024. Since then, ERAS stock has decreased by 18.3% and is now trading at $1.74.
View the best growth stocks for 2024 here.
When is Erasca's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ERAS earnings forecast.
How were Erasca's earnings last quarter?: Erasca, Inc. (NASDAQ:ERAS) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.05.

What ETF holds Erasca's stock?: Loncar China Biopharma ETF holds 137,992 shares of ERAS stock, representing 1.26% of its portfolio.
When did Erasca IPO?: Erasca (ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.
Who are Erasca's major shareholders?: Erasca's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (0.01%). Insiders that own company stock include Alexander W Casdin, Bihua Chen, Jonathan E Lim and Valerie Denise Harding Start.
View institutional ownership trends.
How do I buy shares of Erasca?: Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ERAS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Erasca (ERAS) Stock Price, News & Analysis

Erasca MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Erasca Stock (NASDAQ:ERAS)

ERAS Stock Price History

ERAS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ERAS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™